Search

Your search keyword '"Jarolim, Petr"' showing total 91 results
Start Over Author "Jarolim, Petr" Journal journal of the american college of cardiology
91 results on '"Jarolim, Petr"'

1. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry

Author

Mahmod, Masliza, Jacoby, Daniel, White, James, Chiribiri, Amedeo, Helms, Adam, Choudhury, Lubna, Michels, Michelle, Bradlow, William, Salerno, Michael, Heitner, Stephen, Prasad, Sanjay, Mohiddin, Saidi, Swoboda, Peter, Mahrholdt, Heiko, Bucciarelli-Ducci, Chiara, Weinsaft, Jonathan, Kim, Han, McCann, Gerry, van Rossum, Albert, Williamson, Eric, Flett, Andrew, Dawson, Dana, Mongeon, F. Pierre, Olivotto, Iacopo, Crean, Andrew, Owens, Anjali, Anderson, Lisa, Biagini, Elena, Newby, David, Berry, Colin, Kim, Bette, Larose, Eric, Abraham, Theodore, Sherrid, Mark, Nagueh, Sherif, Rimoldi, Ornella, Elstein, Eleanor, Autore, Camillo, Neubauer, Stefan, Kolm, Paul, Ho, Carolyn Y., Kwong, Raymond Y., Desai, Milind Y., Dolman, Sarahfaye F., Appelbaum, Evan, Desvigne-Nickens, Patrice, DiMarco, John P., Friedrich, Matthias G., Geller, Nancy, Harper, Andrew R., Jarolim, Petr, Jerosch-Herold, Michael, Kim, Dong-Yun, Maron, Martin S., Schulz-Menger, Jeanette, Piechnik, Stefan K., Thomson, Kate, Zhang, Cheng, Watkins, Hugh, Weintraub, William S., and Kramer, Christopher M.

Published
2019
Full Text
View/download PDF

3. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure

Author

Docherty, Kieran F., primary, McDowell, Kirsty, additional, Welsh, Paul, additional, Osmanska, Joanna, additional, Anand, Inder, additional, de Boer, Rudolf A., additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Martinez, Felipe A., additional, O’Meara, Eileen, additional, Ponikowski, Piotr, additional, Schou, Morten, additional, Berg, David D., additional, Sabatine, Marc S., additional, Morrow, David A., additional, Jarolim, Petr, additional, Hammarstedt, Ann, additional, Sjöstrand, Mikaela, additional, Langkilde, Anna Maria, additional, Solomon, Scott D., additional, Sattar, Naveed, additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

5. GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL

Author

Berg, David, primary, Docherty, Kieran F., additional, Talebi, Atefeh, additional, Sattar, Naveed, additional, Jarolim, Petr, additional, Welsh, Paul, additional, Jhund, Pardeep, additional, Anand, Inderjit S., additional, De Boer, Rudolf A., additional, Kosiborod, Mikhail, additional, Kober, Lars, additional, Martinez, Felipe A., additional, O'Meara, Eileen, additional, Ponikowski, Piotr, additional, Schou, Morten, additional, Solomon, Scott D., additional, Hammarstedt, Ann, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, Sabatine, Marc Steven, additional, and Morrow, David A., additional

Published
2023
Full Text
View/download PDF

6. CA125 IN PATIENTS WITH HFREF AND THE EFFECT OF DAPAGLIFLOZIN: INSIGHTS FROM DAPA-HF

Author

McMurray, John J.V., primary, Docherty, Kieran F., additional, Welsh, Paul, additional, Anand, Inderjit S., additional, Berg, David, additional, De Boer, Rudolf A., additional, Jarolim, Petr, additional, Kober, Lars, additional, Kosiborod, Mikhail, additional, Martinez, Felipe A., additional, O'Meara, Eileen, additional, Morrow, David A., additional, Ponikowski, Piotr, additional, Sabatine, Marc Steven, additional, Sattar, Naveed, additional, Schou, Morten, additional, Hammarstedt, Ann, additional, Langkilde, Anna Maria, additional, Sjoestrand, Mikaela, additional, Solomon, Scott D., additional, and Jhund, Pardeep, additional

Published
2023
Full Text
View/download PDF

8. FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58

Author

Berg, David, primary, Wiviott, Stephen D., additional, Raz, Itamar, additional, Jarolim, Petr, additional, Goodrich, Erica L., additional, Mosenzon, Ofri, additional, Cahn, Avivit, additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John PH, additional, Gause-Nilsson, Ingrid, additional, Hammarstedt, Ann, additional, Oscarsson, Jan, additional, Sabatine, Marc Steven, additional, and Morrow, David A., additional

Published
2022
Full Text
View/download PDF

9. TARGETED PROTEOMIC PROFILING OF CARDIOGENIC SHOCK IN THE CARDIAC INTENSIVE CARE UNIT: AN ANALYSIS FROM THE CRITICAL CARE CARDIOLOGY TRIALS NETWORK (CCCTN) REGISTRY

Author

Lopes, Mathew, primary, Berg, David, additional, De Paiva Fagundes, Antonio Aurelio, additional, Silva, Danuzia, additional, Bhatt, Ankeet, additional, Butler, Kayleigh, additional, Jarolim, Petr, additional, Levangie, Michael W., additional, Senman, Balim, additional, Tang, Minao, additional, Varshney, Anubodh, additional, Bohula, Erin, additional, and Morrow, David A., additional

Published
2022
Full Text
View/download PDF

10. CIRCULATING BIOMARKER PATTERNS IN PATIENTS WITH VASODILATORY CARDIOGENIC SHOCK IN THE CARDIAC INTENSIVE CARE UNIT: ANALYSIS FROM THE CRITICAL CARE CARDIOLOGY TRIALS NETWORK (CCCTN) REGISTRY

Author

Senman, Balimkiz, primary, Lopes, Mathew, additional, Silva, Danuzia, additional, Antonio, Fagundes, additional, Berg, David, additional, Bhatt, Ankeet, additional, Butler, Kayleigh, additional, Jarolim, Petr, additional, Levangie, Michael W., additional, Tang, Minao, additional, Varshney, Anubodh, additional, Morrow, David A., additional, and Bohula, Erin Ann, additional

Published
2022
Full Text
View/download PDF

14. Cardiovascular Mortality After Type 1 and Type 2 Myocardial Infarction in Young Adults

Author

Singh, Avinainder, primary, Gupta, Ankur, additional, DeFilippis, Ersilia M., additional, Qamar, Arman, additional, Biery, David W., additional, Almarzooq, Zaid, additional, Collins, Bradley, additional, Fatima, Amber, additional, Jackson, Candace, additional, Galazka, Patrycja, additional, Ramsis, Mattheus, additional, Pipilas, Daniel C., additional, Divakaran, Sanjay, additional, Cawley, Mary, additional, Hainer, Jon, additional, Klein, Josh, additional, Jarolim, Petr, additional, Nasir, Khurram, additional, Januzzi, James L., additional, Di Carli, Marcelo F., additional, Bhatt, Deepak L., additional, and Blankstein, Ron, additional

Published
2020
Full Text
View/download PDF

15. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry

Author

Neubauer, Stefan, primary, Kolm, Paul, additional, Ho, Carolyn Y., additional, Kwong, Raymond Y., additional, Desai, Milind Y., additional, Dolman, Sarahfaye F., additional, Appelbaum, Evan, additional, Desvigne-Nickens, Patrice, additional, DiMarco, John P., additional, Friedrich, Matthias G., additional, Geller, Nancy, additional, Harper, Andrew R., additional, Jarolim, Petr, additional, Jerosch-Herold, Michael, additional, Kim, Dong-Yun, additional, Maron, Martin S., additional, Schulz-Menger, Jeanette, additional, Piechnik, Stefan K., additional, Thomson, Kate, additional, Zhang, Cheng, additional, Watkins, Hugh, additional, Weintraub, William S., additional, Kramer, Christopher M., additional, Mahmod, Masliza, additional, Jacoby, Daniel, additional, White, James, additional, Chiribiri, Amedeo, additional, Helms, Adam, additional, Choudhury, Lubna, additional, Michels, Michelle, additional, Bradlow, William, additional, Salerno, Michael, additional, Heitner, Stephen, additional, Prasad, Sanjay, additional, Mohiddin, Saidi, additional, Swoboda, Peter, additional, Mahrholdt, Heiko, additional, Bucciarelli-Ducci, Chiara, additional, Weinsaft, Jonathan, additional, Kim, Han, additional, McCann, Gerry, additional, van Rossum, Albert, additional, Williamson, Eric, additional, Flett, Andrew, additional, Dawson, Dana, additional, Mongeon, F. Pierre, additional, Olivotto, Iacopo, additional, Crean, Andrew, additional, Owens, Anjali, additional, Anderson, Lisa, additional, Biagini, Elena, additional, Newby, David, additional, Berry, Colin, additional, Kim, Bette, additional, Larose, Eric, additional, Abraham, Theodore, additional, Sherrid, Mark, additional, Nagueh, Sherif, additional, Rimoldi, Ornella, additional, Elstein, Eleanor, additional, and Autore, Camillo, additional

Published
2019
Full Text
View/download PDF

21. WOMEN WHO EXPERIENCE MYOCARDIAL INFARCTION AT A YOUNG AGE HAVE WORSE SURVIVAL COMPARED WITH MEN

Author

Collins, Bradley, primary, Singh, Avinainder, additional, Qamar, Arman, additional, Divakaran, Sanjay, additional, Baez, Julio, additional, Klein, Josh, additional, Hainer, Jon, additional, Jarolim, Petr, additional, Shah, Ravi, additional, Plutzky, Jorge, additional, Polk, Donna, additional, Nasir, Khurram, additional, Carli, Marcelo Di, additional, Bhatt, Deepak, additional, and Blankstein, Ron, additional

Published
2017
Full Text
View/download PDF

23. LIPID ABNORMALITIES IN YOUNG PATIENTS WITH MYOCARDIAL INFARCTION

Author

Collins, Bradley, primary, Singh, Avinainder, additional, Qamar, Arman, additional, Divakaran, Sanjay, additional, Klein, Josh, additional, Hainer, Jon, additional, Jarolim, Petr, additional, Shah, Ravi, additional, Plutzky, Jorge, additional, Polk, Donna, additional, Carli, Marcelo Di, additional, Nasir, Khurram, additional, Bhatt, Deepak, additional, and Blankstein, Ron, additional

Published
2017
Full Text
View/download PDF

26. Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease

Author

Bonaca, Marc P., primary, O’Malley, Ryan G., additional, Jarolim, Petr, additional, Scirica, Benjamin M., additional, Murphy, Sabina A., additional, Conrad, Michael J., additional, Cannon, Christopher P., additional, White, Harvey D., additional, Braunwald, Eugene, additional, Morrow, David A., additional, and Sabatine, Marc S., additional

Published
2016
Full Text
View/download PDF

28. GALECTIN-3 FOR HEART FAILURE RISK STRATIFICATION IN PATIENTS AFTER ACUTE CORONARY SYNDROMES (ACS): INSIGHTS FROM THE SOLID-TIMI 52 TRIAL

Author

Magnani, Giulia, primary, O’Donoghue, Michelle, additional, Braunwald, Eugene, additional, Steen, Dylan, additional, Jarolim, Petr, additional, Lukas, Mary Ann, additional, White, Harvey, additional, Lewis, Basil, additional, de Winter, Robbert, additional, Zhou, Jing, additional, Im, Kyungah, additional, Cannon, Christopher, additional, and Morrow, David, additional

Published
2015
Full Text
View/download PDF

29. PROGNOSTIC UTILITY OF FIBROBLAST GROWTH FACTOR-23 AFTER AN ACUTE CORONARY SYNDROME

Author

Udell, Jacob A., primary, Morrow, David, additional, Braunwald, Eugene, additional, Cannon, Christopher, additional, Steen, Dylan, additional, Jarolim, Petr, additional, Lukas, Mary Ann, additional, Budaj, Andrzej, additional, Hamm, Christian, additional, Zhou, Jing, additional, Im, KyungAh, additional, Sabatine, Marc, additional, and O’Donoghue, Michelle, additional

Published
2015
Full Text
View/download PDF

30. Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease

Author

Udell, Jacob A., primary, Morrow, David A., additional, Jarolim, Petr, additional, Sloan, Sarah, additional, Hoffman, Elaine B., additional, O'Donnell, Thomas F., additional, Vora, Amit N., additional, Omland, Torbjørn, additional, Solomon, Scott D., additional, Pfeffer, Marc A., additional, Braunwald, Eugene, additional, and Sabatine, Marc S., additional

Published
2014
Full Text
View/download PDF

31. PROGNOSTIC IMPLICATIONS OF SIMULTANEOUS BIOMARKER ASSESSMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL

Author

Scirica, Benjamin, primary, Bhatt, Deepak, additional, Braunwald, Eugene, additional, Raz, Itamar, additional, Steg, Philippe, additional, Davidson, Jaime, additional, Cavender, Matthew, additional, Hirshberg, Boaz, additional, Umez-Eronini, Amarachi, additional, Im, Kelly, additional, Jarolim, Petr, additional, and Morrow, David, additional

Published
2014
Full Text
View/download PDF

32. RELATIONSHIP BETWEEN DOSE, ANTI-FACTOR XA ACTIVITY, AND OUTCOMES IN PATIENTS RANDOMIZED TO EDOXABAN IN THE ENGAGE AF-TIMI 48 TRIAL

Author

Ruff, Christian T., primary, Giugliano, Robert, additional, Braunwald, Eugene, additional, Morrow, David, additional, Murphy, Sabina, additional, Deenadayalu, Naveen, additional, Jarolim, Petr, additional, Betcher, Joshua, additional, Shi, Minggao, additional, Brown, Karen S., additional, Patel, Indravadan, additional, Mercuri, Michele, additional, and Antman, Elliott, additional

Published
2014
Full Text
View/download PDF

33. CARDIAC TROPONIN I AND B-TYPE NATRIURETIC PEPTIDE PREDICT CLINICAL OUTCOMES IN STABLE RENAL TRANSPLANT RECIPIENTS

Author

Jarolim, Petr, primary, Claggett, Brian, additional, Pfeffer, Marc, additional, Ivanova, Anastasia, additional, Carpenter, Myra A., additional, Bostom, Andrew, additional, Kusek, John, additional, Hunsicker, Lawrence G., additional, Gravens-Mueller, Lisa, additional, Jacques, Paul F., additional, Finn, Peter, additional, Solomon, Scott, additional, and Levey, Andrew S., additional

Published
2014
Full Text
View/download PDF

43. C-TERMINAL PROVASOPRESSIN (COPEPTIN), MID-REGION PRO-ADRENOMEDULLIN (MR-PROADM) AND MID-REGION PRO-ATRIAL NATRIURETIC PEPTIDE (MR-PROANP) AS NOVEL PROGNOSTIC BIOMARKERS AFTER NON-ST ELEVATION ACUTE CORONARY SYNDROME: ANALYSIS FROM MERLIN TIMI-36

Author

O'Malley, Ryan G., primary, Bonaca, Marc P., additional, Sabatine, Marc S., additional, Scirica, Benjamin M., additional, Murphy, Sabina A., additional, Jarolim, Petr, additional, Braunwald, Eugene, additional, and Morrow, David A., additional

Published
2011
Full Text
View/download PDF

49. B-Type Natriuretic Peptide and the Effect of Ranolazine in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Observations From the MERLIN–TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary–Thrombolysis In Myocardial Infarction 36) Trial

Author

Morrow, David A., Scirica, Benjamin M., Sabatine, Marc S., de Lemos, James A., Murphy, Sabina A., Jarolim, Petr, Theroux, Pierre, Bode, Christophe, and Braunwald, Eugene

Subjects
angina, unstable angina, myocardial infarction, cardiovascular diseases, ranolazine, natriuretic peptides
Abstract

ObjectivesWe designed a prospective evaluation of the interaction between B-type natriuretic peptide (BNP) and the effect of ranolazine in patients with acute coronary syndromes (ACS) as part of a randomized, blinded, placebo-controlled trial.BackgroundRanolazine is believed to exert anti-ischemic effects by reducing myocardial sodium and calcium overload and consequently ventricular wall stress. BNP increases in response to increased wall stress and is a strong risk indicator in ACS.MethodsWe measured plasma BNP in all available baseline samples (n = 4,543) among patients with non–ST-segment elevation ACS randomized to ranolazine or placebo in the MERLIN–TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST Elevation Acute Coronary–Thrombolysis In Myocardial Infarction 36) trial and followed them for a mean of 343 days. The primary end point was a composite of cardiovascular death, myocardial infarction, and recurrent ischemia. BNP elevation was defined as >80 pg/ml.ResultsPatients with elevated BNP (n = 1,935) were at significantly higher risk of the primary trial end point (26.4% vs. 20.4%, p < 0.0001), cardiovascular death (8.0% vs. 2.1%, p < 0.001), and myocardial infarction (10.6% vs. 5.8%, p < 0.001) at 1 year. In patients with BNP >80 pg/ml, ranolazine reduced the primary end point (hazard ratio [HR]: 0.79; 95% confidence interval [CI]: 0.66 to 0.94, p = 0.009). The effect of ranolazine in patients with BNP >80 pg/ml was directionally similar for recurrent ischemia (HR: 0.78; 95% CI: 0.62 to 0.98; p = 0.04) and cardiovascular death or myocardial infarction (HR: 0.83; 95% CI: 0.66 to 1.05, p = 0.12). There was no detectable effect in those with low BNP (p interaction value = 0.05).ConclusionsOur findings indicate that ranolazine may have enhanced efficacy in high-risk patients with ACS identified by increased BNP. The interaction of biomarkers of hemodynamic stress and the effects of ranolazine warrants additional investigation. (Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST Elevation Acute Coronary Syndromes; NCT00099788)

Full Text
View/download PDF

50. Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Results From the A to Z Trial

Author

de Lemos, James A., Morrow, David A., Blazing, Michael A., Jarolim, Petr, Wiviott, Stephen D., Sabatine, Marc S., Califf, Robert M., and Braunwald, Eugene

Abstract

ObjectivesThis study sought to determine whether the novel biomarker monocyte chemoattractant protein (MCP)-1 adds prognostic value to standard risk assessment tools and biomarkers after acute coronary syndromes (ACS).BackgroundMonocyte chemoattractant protein-1 is a chemokine recruiting signal for monocytes that may function as both a mediator and biomarker of ACS.MethodsMonocyte chemoattractant protein-1 was measured at baseline (n = 4,244), 4 months (n = 3,603), and 12 months (n = 2,950), and correlated with clinical events in the Z phase of the A to Z (Aggrastat to Zocor) trial, which compared early intensive versus delayed and less intensive statin therapy after ACS.ResultsRates of death and the composite end points of death or myocardial infarction (MI); death, MI, or heart failure; and cardiovascular death, MI, readmission for ACS, or stroke increased across baseline quartiles of MCP-1 and among patients with MCP-1 greater than versus less than or equal to the pre-specified threshold of 238 pg/ml (p < 0.01 for each). After adjustment for standard risk predictors and levels of C-reactive protein and B-type natriuretic peptide, MCP-1 >238 pg/ml remained independently associated with mortality (hazard ratio 2.16; 95% confidence interval 1.54 to 3.02) and with each composite end point, and increased the C-statistic of the fully adjusted mortality model from 0.76 to 0.78 (p < 0.0001). A value of MCP-1 >238 pg/ml at the 4-month follow-up visit was also independently associated with mortality after 4 months (hazard ratio 1.76; 95% confidence interval 1.12 to 2.76). Elevated MCP-1 levels did not identify patients who derived incremental benefit from intensive statin therapy.ConclusionsMonocyte chemoattractant protein-1 provides independent prognostic value in the acute and chronic phases after ACS and merits further evaluation as a prognostic marker and potential therapeutic target.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results